Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections
There are no currently approved treatments for filovirus infections. In this study we report the discovery process which led to the development of antisense Phosphorodiamidate Morpholino Oligomers (PMOs) AVI-6002 (composed of AVI-7357 and AVI-7539) and AVI-6003 (composed of AVI-7287 and AVI-7288) ta...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2012-11-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1999-4915/4/11/2806 |
| _version_ | 1818201793680637952 |
|---|---|
| author | Sina Bavari Rekha G. Panchal Dan V. Mourich Lisa S. Welch Nicole L. Garza Jay B. Wells Travis K. Warren Patrick L. Iversen |
| author_facet | Sina Bavari Rekha G. Panchal Dan V. Mourich Lisa S. Welch Nicole L. Garza Jay B. Wells Travis K. Warren Patrick L. Iversen |
| author_sort | Sina Bavari |
| collection | DOAJ |
| description | There are no currently approved treatments for filovirus infections. In this study we report the discovery process which led to the development of antisense Phosphorodiamidate Morpholino Oligomers (PMOs) AVI-6002 (composed of AVI-7357 and AVI-7539) and AVI-6003 (composed of AVI-7287 and AVI-7288) targeting Ebola virus and Marburg virus respectively. The discovery process involved identification of optimal transcript binding sites for PMO based RNA-therapeutics followed by screening for effective viral gene target in mouse and guinea pig models utilizing adapted viral isolates. An evolution of chemical modifications were tested, beginning with simple Phosphorodiamidate Morpholino Oligomers (PMO) transitioning to cell penetrating peptide conjugated PMOs (PPMO) and ending with PMOplus containing a limited number of positively charged linkages in the PMO structure. The initial lead compounds were combinations of two agents targeting separate genes. In the final analysis, a single agent for treatment of each virus was selected, AVI-7537 targeting the VP24 gene of Ebola virus and AVI-7288 targeting NP of Marburg virus, and are now progressing into late stage clinical development as the optimal therapeutic candidates. |
| first_indexed | 2024-12-12T02:59:12Z |
| format | Article |
| id | doaj.art-8bcd71df6f9849799231e5fe559e99b0 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-12-12T02:59:12Z |
| publishDate | 2012-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-8bcd71df6f9849799231e5fe559e99b02022-12-22T00:40:40ZengMDPI AGViruses1999-49152012-11-014112806283010.3390/v4112806Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus InfectionsSina BavariRekha G. PanchalDan V. MourichLisa S. WelchNicole L. GarzaJay B. WellsTravis K. WarrenPatrick L. IversenThere are no currently approved treatments for filovirus infections. In this study we report the discovery process which led to the development of antisense Phosphorodiamidate Morpholino Oligomers (PMOs) AVI-6002 (composed of AVI-7357 and AVI-7539) and AVI-6003 (composed of AVI-7287 and AVI-7288) targeting Ebola virus and Marburg virus respectively. The discovery process involved identification of optimal transcript binding sites for PMO based RNA-therapeutics followed by screening for effective viral gene target in mouse and guinea pig models utilizing adapted viral isolates. An evolution of chemical modifications were tested, beginning with simple Phosphorodiamidate Morpholino Oligomers (PMO) transitioning to cell penetrating peptide conjugated PMOs (PPMO) and ending with PMOplus containing a limited number of positively charged linkages in the PMO structure. The initial lead compounds were combinations of two agents targeting separate genes. In the final analysis, a single agent for treatment of each virus was selected, AVI-7537 targeting the VP24 gene of Ebola virus and AVI-7288 targeting NP of Marburg virus, and are now progressing into late stage clinical development as the optimal therapeutic candidates.http://www.mdpi.com/1999-4915/4/11/2806EbolaMarburgPhosphorodiamidate Morpholino OligomerPMOplustherapeuticantiviral |
| spellingShingle | Sina Bavari Rekha G. Panchal Dan V. Mourich Lisa S. Welch Nicole L. Garza Jay B. Wells Travis K. Warren Patrick L. Iversen Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections Viruses Ebola Marburg Phosphorodiamidate Morpholino Oligomer PMOplus therapeutic antiviral |
| title | Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections |
| title_full | Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections |
| title_fullStr | Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections |
| title_full_unstemmed | Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections |
| title_short | Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections |
| title_sort | discovery and early development of avi 7537 and avi 7288 for the treatment of ebola virus and marburg virus infections |
| topic | Ebola Marburg Phosphorodiamidate Morpholino Oligomer PMOplus therapeutic antiviral |
| url | http://www.mdpi.com/1999-4915/4/11/2806 |
| work_keys_str_mv | AT sinabavari discoveryandearlydevelopmentofavi7537andavi7288forthetreatmentofebolavirusandmarburgvirusinfections AT rekhagpanchal discoveryandearlydevelopmentofavi7537andavi7288forthetreatmentofebolavirusandmarburgvirusinfections AT danvmourich discoveryandearlydevelopmentofavi7537andavi7288forthetreatmentofebolavirusandmarburgvirusinfections AT lisaswelch discoveryandearlydevelopmentofavi7537andavi7288forthetreatmentofebolavirusandmarburgvirusinfections AT nicolelgarza discoveryandearlydevelopmentofavi7537andavi7288forthetreatmentofebolavirusandmarburgvirusinfections AT jaybwells discoveryandearlydevelopmentofavi7537andavi7288forthetreatmentofebolavirusandmarburgvirusinfections AT traviskwarren discoveryandearlydevelopmentofavi7537andavi7288forthetreatmentofebolavirusandmarburgvirusinfections AT patrickliversen discoveryandearlydevelopmentofavi7537andavi7288forthetreatmentofebolavirusandmarburgvirusinfections |